These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27548524)

  • 1. Reducing radiation-induced gastrointestinal toxicity - the role of the PHD/HIF axis.
    Olcina MM; Giaccia AJ
    J Clin Invest; 2016 Oct; 126(10):3708-3715. PubMed ID: 27548524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PHD inhibition mitigates and protects against radiation-induced gastrointestinal toxicity via HIF2.
    Taniguchi CM; Miao YR; Diep AN; Wu C; Rankin EB; Atwood TF; Xing L; Giaccia AJ
    Sci Transl Med; 2014 May; 6(236):236ra64. PubMed ID: 24828078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hypoxia-inducible factor pathway, prolyl hydroxylase domain protein inhibitors, and their roles in bone repair and regeneration.
    Fan L; Li J; Yu Z; Dang X; Wang K
    Biomed Res Int; 2014; 2014():239356. PubMed ID: 24895555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
    Requena-Ibáñez JA; Santos-Gallego CG; Rodriguez-Cordero A; Zafar MU; Badimon JJ
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1187-1196. PubMed ID: 34533692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
    Tanaka T; Eckardt KU
    Semin Nephrol; 2018 May; 38(3):267-276. PubMed ID: 29753402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition in cardiometabolic diseases.
    Koivunen P; Serpi R; Dimova EY
    Pharmacol Res; 2016 Dec; 114():265-273. PubMed ID: 27832958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2α-dependent mechanism.
    Riopel M; Moon JS; Bandyopadhyay GK; You S; Lam K; Liu X; Kisseleva T; Brenner D; Lee YS
    Mol Metab; 2020 Nov; 41():101039. PubMed ID: 32534258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
    Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C
    Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.
    Kim SY; Yang EG
    Molecules; 2015 Nov; 20(11):20551-68. PubMed ID: 26610437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.
    Zhou J; Li J; Rosenbaum DM; Zhuang J; Poon C; Qin P; Rivera K; Lepore J; Willette RN; Hu E; Barone FC
    PLoS One; 2017; 12(9):e0184049. PubMed ID: 28880966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis.
    Bakshi HA; Mishra V; Satija S; Mehta M; Hakkim FL; Kesharwani P; Dua K; Chellappan DK; Charbe NB; Shrivastava G; Rajeshkumar S; Aljabali AA; Al-Trad B; Pabreja K; Tambuwala MM
    Inflammation; 2019 Dec; 42(6):2032-2036. PubMed ID: 31377947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Fluorescent Benzo[g]isoquinoline-Based HIF Prolyl Hydroxylase Inhibitor for Cellular Imaging.
    Mayer M; Fey K; Heinze E; Wick CR; Abboud MI; Yeh TL; Tumber A; Orth N; Schley G; Buchholz B; Clark T; Schofield CJ; Willam C; Burzlaff N
    ChemMedChem; 2019 Jan; 14(1):94-99. PubMed ID: 30380199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
    Hasegawa S; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioprotection: the non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins.
    Lee TK; Stupans I
    J Pharm Pharmacol; 2002 Nov; 54(11):1435-45. PubMed ID: 12495545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-adaptive pathways: A pharmacological target in fibrotic disease?
    Strowitzki MJ; Ritter AS; Kimmer G; Schneider M
    Pharmacol Res; 2019 Sep; 147():104364. PubMed ID: 31376431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolyl hydroxylase inhibitors protect from the bone loss in ovariectomy rats by increasing bone vascularity.
    Liu X; Tu Y; Zhang L; Qi J; Ma T; Deng L
    Cell Biochem Biophys; 2014 May; 69(1):141-9. PubMed ID: 24242187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases.
    Eltzschig HK; Bratton DL; Colgan SP
    Nat Rev Drug Discov; 2014 Nov; 13(11):852-69. PubMed ID: 25359381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
    Kaplan JM; Sharma N; Dikdan S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of prolyl hydroxylases alters cell metabolism and reverses pre-existing diastolic dysfunction in mice.
    He X; Zeng H; Roman RJ; Chen JX
    Int J Cardiol; 2018 Dec; 272():281-287. PubMed ID: 30177233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat.
    Figg WD; McDonough MA; Chowdhury R; Nakashima Y; Zhang Z; Holt-Martyn JP; Krajnc A; Schofield CJ
    ChemMedChem; 2021 Jul; 16(13):2082-2088. PubMed ID: 33792169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.